Kenvue Inc. (NYSE:KVUE) Shares Purchased by Headlands Technologies LLC

Headlands Technologies LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 231.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,317 shares of the company’s stock after acquiring an additional 23,957 shares during the quarter. Headlands Technologies LLC’s holdings in Kenvue were worth $733,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in KVUE. Norges Bank acquired a new position in shares of Kenvue in the 4th quarter worth $521,348,000. State Street Corp increased its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Franklin Resources Inc. increased its stake in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Boston Partners raised its holdings in Kenvue by 36.9% during the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after buying an additional 6,366,097 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Kenvue during the fourth quarter valued at about $98,926,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays boosted their target price on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, March 27th. Piper Sandler raised their target price on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $24.00.

Kenvue Trading Down 0.0 %

NYSE:KVUE opened at $23.87 on Thursday. The company has a market capitalization of $45.62 billion, a P/E ratio of 45.04, a P/E/G ratio of 2.62 and a beta of 1.25. The stock’s 50 day moving average price is $22.50 and its 200 day moving average price is $22.47. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.44%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.